Literature DB >> 15928001

SLE--a disease of clearance deficiency?

L E Munoz1, U S Gaipl, S Franz, A Sheriff, R E Voll, J R Kalden, Martin Herrmann.   

Abstract

Systemic lupus erythematosus (SLE) is a multifactorial disease and its pathogenesis and precise aetiology remain unknown. Under physiological conditions, neither apoptotic nor necrotic cell material is easily found in tissues because of its quick removal by a highly efficient scavenger system. Autoantigens are found in apoptotic and necrotic material and they are recognized by autoimmune sera from SLE patients. The clearance of dying cells is finely regulated by a highly redundant system of receptors on phagocytic cells and bridging molecules, which detect molecules specific for dying cells. Changes on apoptotic and necrotic cell surfaces are extremely important for their recognition and further disposal. Some SLE patients seem to have an impaired ability to clear such apoptotic material from tissues, and this could cause the breakdown of central and peripheral mechanisms of tolerance against self-antigens. In this article, we address the cells, receptors and molecules involved in the clearance process and show how deficiencies in this process may contribute to the aetiopathogenesis of SLE.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15928001     DOI: 10.1093/rheumatology/keh693

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  69 in total

Review 1.  Microparticles as autoadjuvants in the pathogenesis of SLE.

Authors:  David S Pisetsky; Peter E Lipsky
Journal:  Nat Rev Rheumatol       Date:  2010-05-11       Impact factor: 20.543

2.  5-Lipoxygenase-deficient mice infected with Borrelia burgdorferi develop persistent arthritis.

Authors:  Victoria A Blaho; Yan Zhang; Jennifer M Hughes-Hanks; Charles R Brown
Journal:  J Immunol       Date:  2011-01-26       Impact factor: 5.422

3.  Native polymeric forms of properdin selectively bind to targets and promote activation of the alternative pathway of complement.

Authors:  Viviana P Ferreira; Claudio Cortes; Michael K Pangburn
Journal:  Immunobiology       Date:  2010-02-12       Impact factor: 3.144

4.  Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus.

Authors:  William Stohl; Falk Hiepe; Kevin M Latinis; Mathew Thomas; Morton A Scheinberg; Ann Clarke; Cynthia Aranow; Frank R Wellborne; Carlos Abud-Mendoza; Douglas R Hough; Lilia Pineda; Thi-Sau Migone; Z John Zhong; William W Freimuth; W Winn Chatham
Journal:  Arthritis Rheum       Date:  2012-07

5.  Lupus: an overview of the disease and management options.

Authors:  William Maidhof; Olga Hilas
Journal:  P T       Date:  2012-04

6.  IgG autoantibodies against deposited C3 inhibit macrophage-mediated apoptotic cell engulfment in systemic autoimmunity.

Authors:  Karla D Kenyon; Caroline Cole; Fran Crawford; John W Kappler; Joshua M Thurman; Donna L Bratton; Susan A Boackle; Peter M Henson
Journal:  J Immunol       Date:  2011-08-03       Impact factor: 5.422

7.  Ageing is associated with diminished apoptotic cell clearance in vivo.

Authors:  T Aprahamian; Y Takemura; D Goukassian; K Walsh
Journal:  Clin Exp Immunol       Date:  2008-04-16       Impact factor: 4.330

Review 8.  Cyclin-dependent kinase inhibitor drugs as potential novel anti-inflammatory and pro-resolution agents.

Authors:  A E Leitch; C Haslett; A G Rossi
Journal:  Br J Pharmacol       Date:  2009-09-23       Impact factor: 8.739

Review 9.  Toll-like receptor-mediated immune responses in intestinal macrophages; implications for mucosal immunity and autoimmune diseases.

Authors:  Zejun Zhou; Miao Ding; Lei Huang; Gary Gilkeson; Ren Lang; Wei Jiang
Journal:  Clin Immunol       Date:  2016-09-09       Impact factor: 3.969

10.  Relationship between anti-dsDNA, anti-nucleosome and anti-alpha-actinin antibodies and markers of renal disease in patients with lupus nephritis: a prospective longitudinal study.

Authors:  Jessica J Manson; Alexander Ma; Pauline Rogers; Lesley J Mason; Jo H Berden; Johan van der Vlag; David P D'Cruz; David A Isenberg; Anisur Rahman
Journal:  Arthritis Res Ther       Date:  2009-10-14       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.